Etoricoxib (brand name Arcoxia®) is a new COX-2 selective inhibitor from Merck & Co. Doses are 60 to 120 mg/day. The Food and Drug Administration (FDA) is requiring additional safety and efficacy data for etoricoxib before it will issue approval. It has been registered in some European countries, e.g. the United Kingdom. It is also available and promoted in India, along with celecoxib. It is for the treatment of rheumatoid arthritis, osteoarthritis, chronic low back pain, gout, and ankylosing spondylitis.

Non-steroidal anti-inflammatory drugs

Etoricoxib | Étoricoxib | Etoricoxib